Literature DB >> 16189129

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.

Marta Boffito1, Anton Pozniak, Brian P Kearney, Christopher Higgs, Anita Mathias, Lijie Zhong, Jaymin Shah.   

Abstract

A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when coadministered in 29 healthy volunteers. Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUC(tau)) ratio. No interaction between tenofovir and nelfinavir was observed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16189129      PMCID： PMC1251521          DOI： 10.1128/AAC.49.10.4386-4389.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*.

Authors:  Gabriel Birkus; Miroslav Hájek; Pavel Kramata; Ivan Votruba; Antonín Holý; Berta Otová
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in HIV infection: current status and future directions.

Authors:  David Back; Giorgio Gatti; Courtney Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo-Federico Perno
Journal:  AIDS       Date:  2002-03       Impact factor: 4.177

3.  The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

Authors:  Guido Kruse; Stefan Esser; Hartmut Stocker; Antje Breske; Andreas Koerber; Maija Kopperman; Heidi Wiehler; Birgit Ross; Christiane Möcklinghoff; Andrew Hill; Mark Becker; Michael Kurowski
Journal:  Antivir Ther       Date:  2005

4.  Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

Authors:  Marta Boffito; David Back; Meredith Stainsby-Tron; Andrew Hill; Giovanni Di Perri; Graeme Moyle; Mark Nelson; Jaqui Tomkins; Brian Gazzard; Anton Pozniak
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

5.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

6.  Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

Authors:  Kathleen Squires; Anton L Pozniak; Gerald Pierone; Corklin R Steinhart; Daniel Berger; Nicholaos C Bellos; Stephen L Becker; Michael Wulfsohn; Michael D Miller; John J Toole; Dion F Coakley; Andrew Cheng
Journal:  Ann Intern Med       Date:  2003-09-02       Impact factor: 25.391
  6 in total
  11 in total

1.  Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.

Authors:  Tim R Cressey; Oraphan Siriprakaisil; Rachel W Kubiak; Virat Klinbuayaem; Pra-Ornsuda Sukrakanchana; Justice Quame-Amaglo; Hideaki Okochi; Yardpiroon Tawon; Ratchada Cressey; Jared M Baeten; Monica Gandhi; Paul K Drain
Journal:  Int J Infect Dis       Date:  2020-06-14       Impact factor: 3.623

2.  Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Ann E Carlson; Kim C Mansky
Journal:  Biochem Biophys Res Commun       Date:  2010-02-18       Impact factor: 3.575

3.  Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.

Authors:  Iwen F Grigsby; Lan Pham; Raj Gopalakrishnan; Louis M Mansky; Kim C Mansky
Journal:  Biochem Biophys Res Commun       Date:  2009-12-21       Impact factor: 3.575

4.  Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.

Authors:  Gregory E Chittick; Jian Zong; M Robert Blum; Jeffrey J Sorbel; John A Begley; Nathalie Adda; Brian P Kearney
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.

Authors:  Sihem Benaboud; Déborah Hirt; Odile Launay; Emmanuelle Pannier; Ghislaine Firtion; Elisabeth Rey; Naïm Bouazza; Frantz Foissac; Hélène Chappuy; Saik Urien; Jean Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

6.  Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

Authors:  Leah Tong; Truc K Phan; Kelly L Robinson; Darius Babusis; Robert Strab; Siddhartha Bhoopathy; Ismael J Hidalgo; Gerald R Rhodes; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

7.  Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.

Authors:  Ahizechukwu C Eke; Kensuke Shoji; Brookie M Best; Jeremiah D Momper; Alice M Stek; Tim R Cressey; Mark Mirochnick; Edmund V Capparelli
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.938

8.  Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

Authors:  Winkler G Weinberg; Kimberly Y Smith; Edwin DeJesus; Margaret A Fischl; Qiming Liao; Lisa L Ross; Gary E Pakes; Keith A Pappa; C Tracey Lancaster
Journal:  AIDS Res Ther       Date:  2008-03-28       Impact factor: 2.250

9.  Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.

Authors:  Nicholas E Thomford; Kevin Dzobo; Denis Chopera; Ambroise Wonkam; Michelle Skelton; Dee Blackhurst; Shadreck Chirikure; Collet Dandara
Journal:  Pharmaceuticals (Basel)       Date:  2015-09-21

Review 10.  The role of drug transporters in the kidney: lessons from tenofovir.

Authors:  Darren M Moss; Megan Neary; Andrew Owen
Journal:  Front Pharmacol       Date:  2014-11-11       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.